@formerfatguyfitness's TRT update claims, fact-checked

What did @formerfatguyfitness actually say?

He's roughly three to four months into testosterone replacement therapy and says most early side effects have resolved. He's also taking HCG (what he calls "H.E.G.") to preserve fertility, using semaglutide ("ratatouille") at around 4mg weekly titrated across two doses, and recently added BPC-157 ("VPC 157") after a significant strain injury. He claims BPC-157 cleared a major strain in about four days. He's also trialing a compound he calls "Tessa Morell" or "Tessa Morellen," which most viewers are interpreting as tesofensine, though the phonetics are ambiguous. He's candid that it's too early to judge that one, and he's honest that semaglutide is "not a cheat code" if you're not controlling calories and protein.

That level of nuance is actually unusual for TikTok wellness content. He's not selling miracles. He explicitly says he can still "eat like an asshole" on semaglutide if he lets himself. Credit where it's due.

Does the science back this up?

On TRT and HCG together, yes, the evidence is solid. On semaglutide, strong. On BPC-157, it's complicated and you should know that. The tesofensine question is harder to answer because it barely exists in approved form anywhere.

TRT with concurrent HCG to preserve testicular function and fertility is well-supported. Hsieh et al. (2013, Fertility and Sterility) confirmed that HCG maintains intratesticular testosterone and sperm production in men on exogenous testosterone. That's not controversial.

Semaglutide's effect on appetite, what he calls "food noise," is backed by real trial data. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed GLP-1 receptor agonists significantly reduce appetite signaling, but weight loss still required behavioral changes. His framing here is accurate.

BPC-157 is where things get murky. Most of the healing data comes from rodent studies. Sikiric et al. have published extensively in journals like Current Pharmaceutical Design and Journal of Physiology-Paris on BPC-157's tissue repair effects in animal models, but robust human clinical trials are essentially nonexistent. His four-day anecdote is compelling to him, and maybe real, but it's impossible to separate from natural healing and placebo in a single self-reported case.

What did they get wrong (or right)?

He got the semaglutide framing right. He got the HCG rationale right. He got BPC-157 partially wrong by implying the evidence is stronger than it is, though he didn't overclaim dramatically. The bigger issue is dosing language around semaglutide.

He says he's "titrating twice a week at about two migs each time, so four migs in total." Standard semaglutide dosing in approved protocols (Ozempic, Wegovy) is weekly, not split twice weekly, and therapeutic doses typically range from 0.25mg to 2.4mg weekly. If he means micrograms, that's a different compound entirely. If he means milligrams and is taking 4mg weekly, that exceeds the approved ceiling dose of 2.4mg weekly for Wegovy. We can't verify his exact compound or formulation, and compounded semaglutide is not equivalent to brand-name approved drugs. That distinction matters clinically.

On "Tessa Morellen": tesofensine is a triple monoamine reuptake inhibitor with some Phase 2 trial data for obesity (Astrup et al., 2008, The Lancet), but it's not approved in the US, and its cardiovascular and psychiatric risk profile is not well characterized in long-term use. Saying "the jury's still out" is underselling the concern level here.

What should you actually know?

If you're considering any part of this stack, the regulatory and safety picture matters as much as the anecdotes.

• TRT for diagnosed hypogonadism is a legitimate, well-studied treatment. It requires ongoing blood work, dose management, and monitoring of hematocrit, estradiol, and lipids. It is not a fitness optimization shortcut for people with normal testosterone.
• HCG alongside TRT is a real clinical tool for fertility preservation, but it should be managed by a provider who is actually monitoring your hormone panel, not a platform that, as this creator experienced, can ghost you.
• Semaglutide works for appetite suppression, but as he correctly notes, it does not override caloric intake on its own. The STEP trials showed meaningful weight loss only alongside lifestyle intervention.
• BPC-157 has interesting animal-model data on tendon and gut healing, but has not cleared Phase 3 human trials. Claiming it healed a strain in four days is anecdote, not evidence. It may also not be legal to obtain in your country.
• Tesofensine has cardiovascular and neurological signals from early trials that make it a higher-risk choice than most people realize. The Lancet Phase 2 data is from 2008, and it has not been approved since for a reason.
• Compounded peptides and hormones vary widely in purity and concentration. They are not interchangeable with pharmaceutical-grade approved drugs.

Bottom line

This creator is more self-aware than most in this space. He acknowledges uncertainty, doesn't claim cures, and explicitly pushes back on the idea that any of this works without diet discipline. But self-awareness doesn't substitute for clinical oversight, and four-day injury recovery stories don't constitute evidence. The BPC-157 and tesofensine portions of his stack involve compounds with thin or absent human trial data. If you're evaluating a similar protocol, that's the part of the conversation worth having with an actual provider, not a Discord server.